HomeInsightsResults

Dr Reddys Laboratories Ltd Quarterly Result

Dr Reddys Laboratories Ltd Quarterly Result

stocks purchased

₹ 7.8 Cr

Volume Transacted

(Nov 21, 2024)

stocks purchased

64.9 K

Stocks Traded

(Nov 21, 2024)

Last Updated on: Nov 22, 2024

Image

Dr Reddys Laboratories Ltd

NSE: DRREDDY

Net Profit

₹ 1341.9

Last updated on: Nov 22, 2024

Key Highlights

  • The revenue of Dr Reddys Laboratories Ltd for the Sep '24 is ₹ 8351 crore as compare to the Jun '24 revenue of ₹ 7889 crore. This represent the growth of 5.8637075%.
  • The ebitda of Dr Reddys Laboratories Ltd for the Sep '24 is ₹ 2390 crore as compare to the Jun '24 ebitda of ₹ 2323 crore. This represent the growth of 2.8885105%.
  • The net profit of Dr Reddys Laboratories Ltd for the Sep '24 is ₹ 1341 crore as compare to the Jun '24 net profit of ₹ 1392 crore. This represent the decline of -3.6268313%.

Results Analysis

Market Price of Dr Reddys Laboratories Ltd

1M

1Y

3Y

5Y

Monitoring Dr Reddys Laboratories Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
21 Nov 20241194.55
19 Nov 20241213.95
18 Nov 20241193.35
14 Nov 20241226.05
13 Nov 20241245.7
12 Nov 20241263.1
11 Nov 20241288.2
08 Nov 20241281.85
07 Nov 20241287.15
06 Nov 20241303

Historical Revenue of Dr Reddys Laboratories Ltd

No data available

* All values are in crore

Historical EBITDA of Dr Reddys Laboratories Ltd

No data available

* All values are in crore

Historical Net Profit of Dr Reddys Laboratories Ltd

No data available

* All values are in crore

Dr Reddys Laboratories Ltd News Hub

News

DRL slips after Hyderabad facility gets 7 observations from USFDA

The GMP inspection was conducted from 13 November 2024 to 19 November 2024. The USFDA issu...

Read more

21 Nov 202410:23

News

DRL's Hyderabad facility gets 7 observations from USFDA

The GMP inspection was conducted from 13 November 2024 to 19 November 2024. The USFDA issu...

Read more

20 Nov 202410:40

News

Mexican health regulator imposes penalty on Dr Reddy's

Dr Reddys Laboratories has received an order dated 12 November 2024, from COFEPRIS (Comisi...

Read more

14 Nov 202409:22

News

Dr Reddys Laboratories Ltd spurts 2.25%

Dr Reddys Laboratories Ltd is up for a third straight session in a row. The stock is quoti...

Read more

06 Nov 202413:05

News

Dr Reddy's Q2 PAT slides 15% YoY to Rs 1,255 crore

Total revenue from operations stood at Rs 8,038.2 crore in Q2 FY25, up 16.45% YoY, primari...

Read more

05 Nov 202417:35

News

Aurigene Oncology receives nod for Phase 2 clinical trial for Ribrecabtagene autoleucel

Aurigene Oncology, a wholly-owned subsidiary of Dr. Reddy's Laboratories has announced the...

Read more

08 Oct 202418:16

Document

Annual Reports

Annual Report 2024

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Aug 2024

Transcript

July 2024

Transcript

May 2024

Transcript

Feb 2024

Transcript

Nov 2023

Transcript

July 2023

TranscriptPPT

May 2023

Transcript

Jan 2023

Transcript

Nov 2022

Transcript

June 2022

TranscriptPPT

Feb 2022

Transcript

Nov 2021

Transcript

Aug 2021

Transcript

May 2021

Transcript

May 2020

Transcript

Jan 2020

Transcript

FAQ's For Dr Reddys Laboratories Ltd Quarterly Result

What is the EPS of Dr Reddys Laboratories Ltd stock?

The Earnings Per Share (EPS) of Dr Reddys Laboratories Ltd is 63.98. An EPS is the amount of net income attributed to each share of a common stock.

How is Dr Reddys Laboratories Ltd EPS calculated?

The EPS of Dr Reddys Laboratories Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Dr Reddys Laboratories Ltd report its EPS?

Dr Reddys Laboratories Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Dr Reddys Laboratories Ltd EPS?

Factors that influence the EPS of Dr Reddys Laboratories Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Dr Reddys Laboratories Ltd EPS growth indicate future performance?

Yes, consistent growth in Dr Reddys Laboratories Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199*